About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.65$ per share.
The book value per share is 7.38$
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -23M | - | -21M | -0.65 | - | - | 33M | 7.38 | -19M | -1M | -20M |